[
  {
    "question": "Effect of hyperventilation on EEG",
    "option_a": "Frontal theta/delta slowing",
    "option_b": "Generalized delta slowing",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Hyperventilation is a standard activation procedure during EEG recordings to provoke latent abnormalities, especially in patients with epilepsy. It leads to physiological changes in the brain\u2019s electrical activity. Hyperventilation causes a reduction in carbon dioxide levels, leading to cerebral vasoconstriction. This results in decreased cerebral blood flow and induces a slowing of the EEG activity, particularly in the frontal regions where the effect is most pronounced. During an EEG, hyperventilation can bring out abnormal rhythms, especially in conditions like absence epilepsy. In normal individuals or in patients without epileptiform discharges, this protocol typically results in frontal theta and delta slowing, which is a benign finding. In an EEG study, hyperventilation is used alongside other activation procedures (such as photic stimulation) to differentiate normal variants from pathological findings. Differential diagnoses include generalized slowing seen in metabolic encephalopathies, but the pattern with hyperventilation is characteristically frontally predominant. This question relates to a diagnostic procedure and not treatment. In the context of EEG activation, hyperventilation is safe to perform in most patients including pregnant women, though care should be taken in those who might experience discomfort. In lactating women, EEG testing poses no risk. A: Frontal theta/delta slowing is correct because hyperventilation reliably induces slowing in the frontal regions. B: Generalized delta slowing is less specific and does not accurately describe the regionally accentuated slowing typically observed. \u2022 Hyperventilation during EEG testing often induces frontal slowing (theta/delta) as a normal variant. \u2022 It is an important activation procedure to help diagnose conditions such as absence epilepsy. \u2022 Understanding the normal effects of hyperventilation aids in avoiding misinterpretation of EEG findings. Recent EEG studies and guidelines confirm that hyperventilation induces a predictable pattern of frontal slowing in the EEG. Advances in neurophysiology continue to refine the understanding of these activation procedures and support their use in routine clinical practice.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario infant with myolconus started focaly and become progressive what to expect on EEG",
    "option_a": "(Burst suppression) is correct because this pattern is specifically associated with severe encephalopathy and advanced disease stages in conditions like PME. Other potential options such as generalized spike",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "This scenario reviews an infant with a progressively evolving myoclonus disorder. In severe early-onset epileptic encephalopathies \u2013 including certain progressive myoclonic epilepsies (PMEs) or neonatal epileptic syndromes \u2013 the EEG often demonstrates distinctive patterns. Burst suppression is one such pattern marked by alternating periods of high\u2010voltage activity (bursts) and nearly flat suppression intervals. Burst suppression reflects severe cortical dysfunction with periods of neuronal hyperactivity (bursts) followed by suppression when almost no electrical activity is detectable. This pattern is observed in severe encephalopathic conditions (e.g., Ohtahara syndrome in neonates or advanced stages of PME) where neuronal networks become critically dysfunctional. Current evidence shows that burst suppression is linked with poor prognosis and represents extensive cortical injury. In an infant with focal onset myoclonus that becomes increasingly generalized, the progression reflects worsening cortical involvement. Clinically, these children may show rapid neurologic deterioration. The burst suppression pattern on EEG supports the presence of severe, diffuse brain dysfunction that correlates with hard\u2010to-control seizures and developmental impairment. When evaluating such infants, differentials include neonatal epileptic encephalopathies like Ohtahara syndrome (which typically has a burst suppression pattern) and early myoclonic encephalopathy. Differentiation is made based on age, clinical presentation (e.g., seizure type, developmental status), and neuroimaging findings. Other EEG patterns (e.g., hypsarrhythmia in West syndrome) help direct the diagnosis. Management of these severe epileptic encephalopathies is challenging. First-line treatment typically includes broad-spectrum antiepileptic drugs, with many cases proving refractory. Options may include ACTH, corticosteroids, or specific regimens for neonatal syndromes. In refractory cases, supportive care and consideration for palliative strategies are important. In pregnancy and lactation, if similar syndromes are encountered in older patients, medications with known safety profiles (e.g., levetiracetam, lamotrigine) are preferred, and multidisciplinary consultation is recommended. Option a (Burst suppression) is correct because this pattern is specifically associated with severe encephalopathy and advanced disease stages in conditions like PME. Other potential options such as generalized spike-and-wave complexes or hypsarrhythmia represent EEG patterns seen in different epileptic syndromes and do not accurately reflect the advanced deterioration seen here. 1. Burst suppression on EEG indicates severe cortical dysfunction and is associated with a poor prognosis. 2. Early infantile epileptic encephalopathies are marked by distinct EEG patterns that guide diagnosis and management. 3. Correlation of clinical progression with EEG evolution is essential in assessing disease severity. Recent studies continue to underscore the prognostic significance of burst suppression patterns in neonatal and infantile encephalopathies. Advanced neuroimaging and molecular diagnostics complement EEG findings in establishing an early diagnosis, although treatment remains largely supportive with emerging research into novel, targeted therapies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient went for dental procedure had brief LOC what favor seizure, not syncope",
    "option_a": "(Cyanosis) is correct. Cyanosis during a LOC episode is unusual in syncope but common in seizures due to respiratory compromise. Other options (if listed) likely fail to capture this key discriminatory feature, making cyanosis a reliable clinical sign to favor seizure over syncope.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "This question focuses on distinguishing between seizure and syncope in a patient who experienced brief loss of consciousness (LOC) after a dental procedure. In the context of a seizure, the pathophysiological mechanism often entails impaired ventilation leading to cyanosis. During a generalized tonic\u2013clonic seizure, there may be apnea or airway obstruction resulting in reduced oxygenation and subsequent cyanosis. By contrast, syncope generally results from transient cerebral hypoperfusion without significant respiratory compromise. The presence of cyanosis during LOC is therefore indicative of the abnormal neuronal hyperactivity seen in seizures. The clinical picture of a brief LOC accompanied by cyanosis should alert clinicians to the possibility of a seizure. Additional signs such as tongue biting, incontinence, or postictal confusion would further support a seizure rather than syncope. In syncope, patients usually experience a rapid return to baseline without these features. Differentials include vasovagal syncope, cardiac syncope, and seizures. A detailed history focusing on the event characteristics, physical exam, and ancillary testing (ECG, EEG) help differentiate these conditions. A history of prodromal symptoms and rapid recovery without postictal disorientation is more suggestive of syncope. The acute management of a seizure involves ensuring airway safety, oxygen supplementation, and monitoring. Long-term management requires evaluation for an underlying epileptic disorder and possibly initiation or adjustment of antiepileptic drugs (AEDs). In patients who are pregnant or lactating, AEDs with favorable safety profiles (such as lamotrigine or levetiracetam) are preferred, with folic acid supplementation recommended during pregnancy. Option a (Cyanosis) is correct. Cyanosis during a LOC episode is unusual in syncope but common in seizures due to respiratory compromise. Other options (if listed) likely fail to capture this key discriminatory feature, making cyanosis a reliable clinical sign to favor seizure over syncope. 1. Cyanosis during a brief LOC is a red flag for a seizure rather than syncope. 2. Seizures are often accompanied by additional signs like tongue biting and postictal confusion. 3. A thorough history is crucial when distinguishing between seizure and syncope. Contemporary studies reinforce the utility of clinical signs (such as cyanosis and postictal confusion) in differentiating seizures from syncope. Updated clinical guidelines promote careful assessment with a combination of history, physical exam, and targeted investigations (including EEG and ECG) to reliably distinguish these entities.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has seizure recurrence on topiramate 200mg and CBZ 400mg bid came with breakthrough seizure what is the cause, EEG pic showed spikes in temporal lobe, and MRI showed MTS, no more details",
    "option_a": "(Drug interactions) is less likely here as no recent changes were mentioned and the drugs involved are commonly coadministered. Option b (MTS) is correct, as the MRI and EEG findings directly point to a structural cause. Option c (Interictal spikes) are simply an electrophysiological marker and do not themselves cause seizures. Option d (Poor compliance) is not supported in the scenario given the provided medication regimen and dosing.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Epilepsy",
    "explanation": "This scenario involves a patient on topiramate and carbamazepine who experiences breakthrough seizures. The key insight provided by the investigations is the presence of mesial temporal sclerosis (MTS) on MRI and temporal lobe spikes on EEG, pinpointing a structural epileptogenic focus as the cause. MTS is characterized by neuronal loss and gliosis in the mesial temporal structures, particularly the hippocampus. This structural abnormality creates a focus for seizure initiation and propagation, leading to refractory temporal lobe epilepsy. Despite the presence of therapeutic doses of AEDs, the structural lesion is a persistent source of epileptogenicity. Patients with MTS typically present with temporal lobe seizures that may be refractory to medical therapy. EEG studies often reveal interictal spikes or sharp waves localized to the temporal lobe, and MRI confirms the diagnosis with findings of hippocampal atrophy and sclerosis. The differential includes drug interaction (which can lower AED levels), poor compliance, and primary EEG findings such as interictal spikes. However, in this case, the MRI finding of MTS is the definitive clue. Differentiation is supported by therapeutic drug monitoring to rule out subtherapeutic levels and ensuring adherence, but the structural lesion remains the primary etiology. For patients with MTS and refractory temporal lobe epilepsy, assessment for epilepsy surgery is crucial. First-line management includes verifying medication compliance and appropriate dosing. If seizures persist, surgical evaluation (such as anterior temporal lobectomy or selective amygdalohippocampectomy) is recommended. In pregnant or lactating women with drug-resistant epilepsy, careful balancing of seizure control with fetal and neonatal safety is required, favoring AEDs with established safety profiles and close monitoring. Option a (Drug interactions) is less likely here as no recent changes were mentioned and the drugs involved are commonly coadministered. Option b (MTS) is correct, as the MRI and EEG findings directly point to a structural cause. Option c (Interictal spikes) are simply an electrophysiological marker and do not themselves cause seizures. Option d (Poor compliance) is not supported in the scenario given the provided medication regimen and dosing. 1. MTS is a well-known cause of refractory temporal lobe epilepsy and should be considered when seizures persist despite therapeutic AED levels. 2. Structural lesions identified on MRI are critical in guiding management decisions, including the possibility of epilepsy surgery. 3. Always correlate EEG findings with imaging studies for a comprehensive evaluation. Recent guidelines recommend early surgical evaluation for patients with drug\u2010resistant temporal lobe epilepsy associated with MTS. There is growing evidence that patients with clearly defined structural lesions like MTS benefit significantly from surgical interventions compared to prolonged medical management alone.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario pt with epileptic spasms and EEG showing hypsarrhythmia, whats the dx (they didn\u2019t say the EEG findings, literally what is the diagnosis)",
    "option_a": "(Hypsarrhythmia) is incorrect because it merely describes the EEG pattern, not the complete clinical diagnosis. Option b (None) is correct because the diagnosis in this context is infantile spasms (West syndrome) and not simply hypsarrhythmia. The clinical scenario directs us to ascertain the full syndrome rather than name the EEG finding.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses the diagnosis in a classic scenario of infantile spasms. Although the EEG shows hypsarrhythmia \u2013 a chaotic, high-amplitude pattern \u2013 the diagnosis is not simply the EEG finding but the clinical syndrome of infantile spasms, also known as West syndrome. Infantile spasms are a type of epileptic encephalopathy seen typically in early infancy. The underlying mechanism involves abnormal brain development and disorganized neuronal circuitry which produces the irregular, high-voltage hypsarrhythmia pattern on EEG. This pattern correlates with a high seizure burden and often progressive neurodevelopmental impairment. Clinically, infantile spasms present as brief contractions or spasms involving the neck, trunk, and extremities, often in clusters and associated with developmental regression. Hypsarrhythmia on EEG is considered a hallmark of this syndrome, supporting the diagnosis of West syndrome when combined with the clinical picture. The differential diagnosis for early-onset spasms includes other neonatal epileptic encephalopathies such as Ohtahara syndrome. However, hypsarrhythmia is a key feature of infantile spasms. A thorough workup includes EEG, neuroimaging, and metabolic studies to rule out secondary causes. First-line treatment for infantile spasms includes high-dose adrenocorticotropic hormone (ACTH) or corticosteroids, with vigabatrin as an alternative, especially in cases related to tuberous sclerosis. In pregnant or lactating women (in the rare scenario that treatment of infantile spasms is considered in overlapping contexts such as in maternal treatment planning), careful consideration of drug safety is essential, and multidisciplinary consultation should occur. Early treatment is critical to improving developmental outcomes. Option a (Hypsarrhythmia) is incorrect because it merely describes the EEG pattern, not the complete clinical diagnosis. Option b (None) is correct because the diagnosis in this context is infantile spasms (West syndrome) and not simply hypsarrhythmia. The clinical scenario directs us to ascertain the full syndrome rather than name the EEG finding. 1. Infantile spasms are characterized by a triad of epileptic spasms, hypsarrhythmia on EEG, and developmental regression. 2. Early recognition and treatment are critical for a better neurodevelopmental outcome. 3. Always differentiate between describing an EEG pattern and assigning a clinical diagnosis. Recent research has focused on the benefits of early and aggressive treatment of infantile spasms, which can modify the long-term neurodevelopmental trajectory. Updated guidelines continue to endorse ACTH as a first-line therapy, with vigabatrin serving as an alternative in specific cases such as tuberous sclerosis.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_26.png"
  },
  {
    "question": "Child with perisylphian atrophy and unilateral weakness, had initially focal seizure then focal status what is the ab",
    "option_a": ", which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses an autoimmune form of focal epilepsy in a child. In such cases, immune\u2010mediated mechanisms, including the development of specific autoantibodies such as GluR3, target discrete areas of the cortex. These antibodies are implicated in the disruption of excitatory neurotransmission, leading to focal seizures that may progress to focal status epilepticus. GluR3 is a subtype of the AMPA receptor. In some children with autoimmune epilepsy, antibodies target GluR3, causing excitotoxic injury in localized brain regions (often the perisylvian area). This antibody\u2010mediated injury results in both structural damage (e.g., regional atrophy) and a reduced threshold for seizure generation, which may manifest as refractory focal seizures or status epilepticus. A child presenting with perisylvian atrophy on neuroimaging and unilateral weakness, together with a history of an initial focal seizure progressing to focal status epilepticus, fits the profile of an autoimmune process. The localizing findings on imaging correlate with regions vulnerable to antibody\u2010mediated injury. The evaluation typically includes high\u2010resolution MRI, EEG studies to assess seizure foci, and laboratory tests such as serum and CSF autoantibody panels. Differential diagnoses include structural brain lesions (e.g., cortical dysplasia), infectious encephalitides, and other autoimmune disorders like NMDA receptor or LGI1 encephalitis. Neurological exam and imaging help differentiate these conditions. The first-line treatment involves immunomodulatory therapies (e.g., corticosteroids, intravenous immunoglobulin, or plasmapheresis) combined with antiepileptic drugs (AEDs). In refractory cases, second-line immunosuppressive agents (such as rituximab or cyclophosphamide) may be considered. Although pregnancy and lactation are less directly relevant in pediatric patients, in pregnant patients with autoimmune epilepsy, one must balance immunotherapy benefits with fetal safety by selecting agents with acceptable pregnancy safety profiles per current guidelines. Option a, which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here. 1. In pediatric refractory focal epilepsy, consider an autoimmune etiology and request specific autoantibody panels. 2. Perisylvian atrophy in children can be a radiological clue to a localized autoimmune process. 3. Early immunotherapy is critical to prevent permanent brain injury. Recent research has further characterized GluR3-related autoimmune epilepsy, with several studies confirming its role in refractory focal seizures. Ongoing clinical trials are examining the efficacy of targeted immunotherapies in these cases, reinforcing the updated understanding in both pediatric neurology and autoimmune neurology guidelines.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "HIV Patient came with seizure what is the culprit medication",
    "option_a": ", which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses an autoimmune form of focal epilepsy in a child. In such cases, immune\u2010mediated mechanisms, including the development of specific autoantibodies such as GluR3, target discrete areas of the cortex. These antibodies are implicated in the disruption of excitatory neurotransmission, leading to focal seizures that may progress to focal status epilepticus. GluR3 is a subtype of the AMPA receptor. In some children with autoimmune epilepsy, antibodies target GluR3, causing excitotoxic injury in localized brain regions (often the perisylvian area). This antibody\u2010mediated injury results in both structural damage (e.g., regional atrophy) and a reduced threshold for seizure generation, which may manifest as refractory focal seizures or status epilepticus. A child presenting with perisylvian atrophy on neuroimaging and unilateral weakness, together with a history of an initial focal seizure progressing to focal status epilepticus, fits the profile of an autoimmune process. The localizing findings on imaging correlate with regions vulnerable to antibody\u2010mediated injury. The evaluation typically includes high\u2010resolution MRI, EEG studies to assess seizure foci, and laboratory tests such as serum and CSF autoantibody panels. Differential diagnoses include structural brain lesions (e.g., cortical dysplasia), infectious encephalitides, and other autoimmune disorders like NMDA receptor or LGI1 encephalitis. Neurological exam and imaging help differentiate these conditions. The first-line treatment involves immunomodulatory therapies (e.g., corticosteroids, intravenous immunoglobulin, or plasmapheresis) combined with antiepileptic drugs (AEDs). In refractory cases, second-line immunosuppressive agents (such as rituximab or cyclophosphamide) may be considered. Although pregnancy and lactation are less directly relevant in pediatric patients, in pregnant patients with autoimmune epilepsy, one must balance immunotherapy benefits with fetal safety by selecting agents with acceptable pregnancy safety profiles per current guidelines. Option a, which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here. 1. In pediatric refractory focal epilepsy, consider an autoimmune etiology and request specific autoantibody panels. 2. Perisylvian atrophy in children can be a radiological clue to a localized autoimmune process. 3. Early immunotherapy is critical to prevent permanent brain injury. Recent research has further characterized GluR3-related autoimmune epilepsy, with several studies confirming its role in refractory focal seizures. Ongoing clinical trials are examining the efficacy of targeted immunotherapies in these cases, reinforcing the updated understanding in both pediatric neurology and autoimmune neurology guidelines.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Long scenario, 11 years old boy has impaired vision, progressive cognitive decline, myoclonic epilepsy, ataxia, brain MRI shows grey matter predominant changes. Biopsy shows lysosomal material. What is the DX?",
    "option_a": "Gaucher disease",
    "option_b": "Neuronal ceroid lipofuscinosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses an autoimmune form of focal epilepsy in a child. In such cases, immune\u2010mediated mechanisms, including the development of specific autoantibodies such as GluR3, target discrete areas of the cortex. These antibodies are implicated in the disruption of excitatory neurotransmission, leading to focal seizures that may progress to focal status epilepticus. GluR3 is a subtype of the AMPA receptor. In some children with autoimmune epilepsy, antibodies target GluR3, causing excitotoxic injury in localized brain regions (often the perisylvian area). This antibody\u2010mediated injury results in both structural damage (e.g., regional atrophy) and a reduced threshold for seizure generation, which may manifest as refractory focal seizures or status epilepticus. A child presenting with perisylvian atrophy on neuroimaging and unilateral weakness, together with a history of an initial focal seizure progressing to focal status epilepticus, fits the profile of an autoimmune process. The localizing findings on imaging correlate with regions vulnerable to antibody\u2010mediated injury. The evaluation typically includes high\u2010resolution MRI, EEG studies to assess seizure foci, and laboratory tests such as serum and CSF autoantibody panels. Differential diagnoses include structural brain lesions (e.g., cortical dysplasia), infectious encephalitides, and other autoimmune disorders like NMDA receptor or LGI1 encephalitis. Neurological exam and imaging help differentiate these conditions. The first-line treatment involves immunomodulatory therapies (e.g., corticosteroids, intravenous immunoglobulin, or plasmapheresis) combined with antiepileptic drugs (AEDs). In refractory cases, second-line immunosuppressive agents (such as rituximab or cyclophosphamide) may be considered. Although pregnancy and lactation are less directly relevant in pediatric patients, in pregnant patients with autoimmune epilepsy, one must balance immunotherapy benefits with fetal safety by selecting agents with acceptable pregnancy safety profiles per current guidelines. Option a, which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here. 1. In pediatric refractory focal epilepsy, consider an autoimmune etiology and request specific autoantibody panels. 2. Perisylvian atrophy in children can be a radiological clue to a localized autoimmune process. 3. Early immunotherapy is critical to prevent permanent brain injury. Recent research has further characterized GluR3-related autoimmune epilepsy, with several studies confirming its role in refractory focal seizures. Ongoing clinical trials are examining the efficacy of targeted immunotherapies in these cases, reinforcing the updated understanding in both pediatric neurology and autoimmune neurology guidelines.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_18.png"
  },
  {
    "question": "Scenario oculomotor apraxia, spasticity, myoclonic seizure, hepatosplenomegally",
    "option_a": ", which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses an autoimmune form of focal epilepsy in a child. In such cases, immune\u2010mediated mechanisms, including the development of specific autoantibodies such as GluR3, target discrete areas of the cortex. These antibodies are implicated in the disruption of excitatory neurotransmission, leading to focal seizures that may progress to focal status epilepticus. GluR3 is a subtype of the AMPA receptor. In some children with autoimmune epilepsy, antibodies target GluR3, causing excitotoxic injury in localized brain regions (often the perisylvian area). This antibody\u2010mediated injury results in both structural damage (e.g., regional atrophy) and a reduced threshold for seizure generation, which may manifest as refractory focal seizures or status epilepticus. A child presenting with perisylvian atrophy on neuroimaging and unilateral weakness, together with a history of an initial focal seizure progressing to focal status epilepticus, fits the profile of an autoimmune process. The localizing findings on imaging correlate with regions vulnerable to antibody\u2010mediated injury. The evaluation typically includes high\u2010resolution MRI, EEG studies to assess seizure foci, and laboratory tests such as serum and CSF autoantibody panels. Differential diagnoses include structural brain lesions (e.g., cortical dysplasia), infectious encephalitides, and other autoimmune disorders like NMDA receptor or LGI1 encephalitis. Neurological exam and imaging help differentiate these conditions. The first-line treatment involves immunomodulatory therapies (e.g., corticosteroids, intravenous immunoglobulin, or plasmapheresis) combined with antiepileptic drugs (AEDs). In refractory cases, second-line immunosuppressive agents (such as rituximab or cyclophosphamide) may be considered. Although pregnancy and lactation are less directly relevant in pediatric patients, in pregnant patients with autoimmune epilepsy, one must balance immunotherapy benefits with fetal safety by selecting agents with acceptable pregnancy safety profiles per current guidelines. Option a, which identifies GluR3 antibodies as the underlying cause, is correct. Other options (for example, NMDA receptor, LGI1, or GABA receptor antibodies) are more typically associated with other clinical syndromes (such as encephalitis with prominent psychiatric symptoms, faciobrachial dystonic seizures, or generalized encephalopathy) and do not explain the focal cortical findings and perisylvian atrophy observed here. 1. In pediatric refractory focal epilepsy, consider an autoimmune etiology and request specific autoantibody panels. 2. Perisylvian atrophy in children can be a radiological clue to a localized autoimmune process. 3. Early immunotherapy is critical to prevent permanent brain injury. Recent research has further characterized GluR3-related autoimmune epilepsy, with several studies confirming its role in refractory focal seizures. Ongoing clinical trials are examining the efficacy of targeted immunotherapies in these cases, reinforcing the updated understanding in both pediatric neurology and autoimmune neurology guidelines.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Young patient presented to neurology outpatient clinic for epilepsy evaluation. He has seizure semiology inform of right upper limb tonic posturing followed by limb jerking with lack of awareness, then bilateral tonic-clonic seizure He doesn\u2019t recall the episode. He has history of 4 car accident one of them required ICU admission for 3 days.\nWhat is the likely localization for his seizure semiology?",
    "option_a": "Premotor",
    "option_b": "Primary motor",
    "option_c": "Supplementary motor area",
    "option_d": "Temporal lobe",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Focal seizures are characterized by an abnormal electrical discharge originating in a specific area of the cortex. In the motor regions of the frontal lobe, different subregions (primary motor, premotor, and supplementary motor areas) produce distinct clinical manifestations. Understanding these nuances helps with localizing the epileptogenic zone based on seizure semiology. When seizure activity begins in the supplementary motor area (SMA), which is located on the medial surface of the frontal lobe and is involved in planning and initiating movement, the discharge typically produces contralateral tonic posturing. Because of the rapid propagation of the ictal activity from the SMA to adjacent networks, including those related to awareness, patients may quickly lose consciousness and the seizure can generalize. This patient exhibits right upper limb tonic posturing followed by limb jerking and impaired awareness, eventually progressing to a bilateral tonic-clonic seizure. Seizures arising from the primary motor cortex generally show a Jacksonian march with preserved awareness for a longer duration, whereas SMA seizures are more likely to be accompanied by early impairment of consciousness. Localization is aided by detailed clinical history, video-EEG monitoring, and neuroimaging such as MRI. Differential diagnoses include seizures from the primary motor cortex (which often produce a Jacksonian march without early impairment of awareness) and temporal lobe seizures (which are commonly preceded by auras and automatisms). According to the 2022 ILAE epilepsy management guidelines, first-line treatment for focal seizures includes antiseizure medications (ASMs) such as levetiracetam, carbamazepine, or lamotrigine, chosen based on patient factors and side effect profiles (ILAE, 2022). In patients with post-traumatic epilepsy presenting with focal motor seizures, ASMs targeting focal cortical hyperexcitability are effective in controlling seizures. The mechanism of ASMs involves modulation of voltage-gated ion channels, enhancement of inhibitory GABAergic transmission, or reduction of excitatory glutamatergic activity. For patients with drug-resistant focal epilepsy localized to premotor cortex, surgical resection or neuromodulation (vagal nerve stimulation, responsive neurostimulation) may be considered. Acute seizure management follows standard protocols with benzodiazepines for status epilepticus. Long-term care includes seizure control, neurorehabilitation for any deficits, and counseling on seizure precautions. Management must be individualized considering the patient\u2019s traumatic brain injury history and potential comorbidities. Option A (Premotor) is correct because the seizure semiology begins with right upper limb tonic posturing followed by jerking, consistent with premotor cortex involvement. The premotor cortex produces tonic posturing due to sustained abnormal activation of motor planning areas before spread to primary motor cortex causing clonic jerking. The progression to bilateral tonic-clonic seizures and impaired awareness fits secondary generalization from a premotor focus.  Option B (Primary motor) is incorrect because primary motor cortex seizures typically present with clonic jerking of the contralateral limb without preceding tonic posturing. The primary motor cortex directly activates lower motor neurons causing rhythmic clonic movements rather than sustained tonic postures.  Option C (Supplementary motor area) is incorrect because SMA seizures often present with bilateral tonic posturing, vocalizations, or complex bilateral motor phenomena, frequently with preserved awareness initially. The unilateral tonic posturing followed by clonic jerking and impaired awareness is less typical for SMA seizures.  Option D (Temporal lobe) is incorrect because temporal lobe seizures usually manifest with aura (epigastric rising sensation, d\u00e9j\u00e0 vu), automatisms, and impaired awareness early on rather than focal motor manifestations like tonic posturing or clonic jerking. The motor symptoms described are not characteristic of temporal lobe onset.  The discriminating feature is the initial tonic posturing localized to contralateral upper limb, which is hallmark of premotor cortex involvement rather than primary motor or SMA or temporal lobe origins. - **Tonic posturing preceding clonic jerking strongly suggests premotor cortex seizure onset.** - **Primary motor cortex seizures typically manifest as clonic jerking without prior tonic phase.** - **SMA seizures often have bilateral motor signs and may preserve awareness early.** - **Temporal lobe seizures rarely produce isolated focal motor signs; look for aura and automatisms.** - History of traumatic brain injury is a common cause of focal epilepsy, often involving motor association cortices. - Video-EEG monitoring is essential to confirm seizure onset zone. - Remember the motor homunculus when localizing motor seizures. - Secondary generalization with impaired awareness indicates spread beyond focal motor areas. - Avoid misclassification by carefully analyzing seizure semiology phases (tonic vs clonic, unilateral vs bilateral). - Use MRI to detect structural lesions that may guide surgical evaluation. The 2022 International League Against Epilepsy (ILAE) guidelines state: \u201cFocal seizures with motor onset presenting with tonic posturing followed by clonic jerking and progression to bilateral tonic-clonic seizures are highly suggestive of premotor cortex origin (ILAE, 2022). Accurate semiological analysis combined with EEG and imaging is critical for localization and management.\u201d  Current evidence supports early use of video-EEG and high-resolution MRI in post-traumatic epilepsy for localization (Kwon et al., 2023). There remains a knowledge gap in differentiating premotor from SMA seizures solely on semiology, emphasizing the importance of multimodal evaluation. Advances in intracranial EEG and functional imaging continue to refine localization, impacting surgical candidacy. Controversies persist regarding the optimal ASM choice in post-traumatic epilepsy, but levetiracetam remains first-line due to favorable side effect profile. Emerging neuromodulation therapies offer options for refractory cases. Overall, integration of detailed clinical semiology with modern diagnostic tools aligns with best practices for seizure localization and treatment.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient presented with history of stroke followed by one episode of seizure inform of generalized tonic-clonic seizure. He is known case of well-controlled bipolar disorder. Which of the following is the appropriate ASMs for this patient?",
    "option_a": "Valproic acid",
    "option_b": "Topiramate",
    "option_c": "Levetiracetam",
    "option_d": "Lacosamide",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "For post\u2010stroke seizures, selecting an antiseizure medication (ASM) should take into account the seizure type as well as any comorbid conditions. In this case, the patient experienced a generalized tonic\u2010clonic seizure and also has well-controlled bipolar disorder. Valproic acid is a broad-spectrum ASM effective in managing generalized seizures and also has mood-stabilizing properties, making it particularly suited for patients with coexisting bipolar disorder. Post-stroke seizures are often due to structural and gliotic brain changes that create an epileptogenic focus. Valproic acid increases the availability of gamma-aminobutyric acid (GABA) in the brain, which helps in stabilizing neuronal firing and preventing seizure propagation. Its additional mood-stabilizing action is linked to modulations in signal transduction pathways that are relevant in bipolar disorder. This patient had a stroke followed by a generalized tonic\u2010clonic seizure, consistent with a remote symptomatic seizure. Given his history of bipolar disorder, it is advantageous to use an ASM that does not destabilize mood. Valproic acid is also used in the management of bipolar disorder, thereby addressing both conditions simultaneously. The work-up for post-stroke seizures generally includes neuroimaging (CT/MRI) to assess the extent of stroke-related brain changes, and an electroencephalogram (EEG) to detect epileptiform discharges. A careful medication review is also essential given the patient\u2019s psychiatric history to avoid potential drug interactions or mood destabilization. Current guidelines recommend tailoring ASM therapy to the patient's comorbid conditions. Valproic acid is appropriate in this case because it effectively manages both generalized seizures and bipolar disorder. However, special pregnancy and lactation considerations are important: valproic acid is highly teratogenic and generally contraindicated in women of childbearing potential unless no suitable alternatives exist, and its use during lactation requires detailed risk-benefit discussion. A: Valproic acid is the optimal choice given its dual efficacy as both an ASM for generalized seizures and a mood stabilizer for bipolar disorder. B: Topiramate, though broad-spectrum, has cognitive side effects and less supportive mood stabilization evidence. C: Levetiracetam is often used in post-stroke seizures but may trigger psychiatric adverse effects, notably irritability or destabilization in bipolar patients. D: Lacosamide is typically reserved for focal seizures and is not a first-line therapy in generalized tonic-clonic seizures. Utilize valproic acid in patients with coexisting seizure disorders and bipolar disorder due to its dual benefits, but remain cautious about its use in women of reproductive potential. Always weigh the risk of teratogenicity and consider alternative agents if pregnancy or lactation is a factor. Recent clinical guidelines and literature affirm the use of valproic acid in cases where both seizure control and mood stabilization are required. Studies have shown that while levetiracetam is favored in many post-stroke scenarios due to its minimal drug interactions, its potential psychiatric side effects make valproic acid a more suitable choice for patients with coexisting mood disorders.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 25-year-old pregnant lady came to the outpatient neurology clinic for follow-up. She is known case of epilepsy and currently on Valproic acid 500 mg daily. Last time she had a breakthrough seizure was at least 3 years ago. Her last EEG and brain MRI were normal. Which of the following is the appropriate management?",
    "option_a": "Stop Valproic acid",
    "option_b": "Switch to Lamotrigine",
    "option_c": "Quality of life counseling",
    "option_d": "Counsel her about breast feeding",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "In the management of epilepsy during pregnancy, the overriding principle is maintaining stable seizure control. This is critical because breakthrough seizures during pregnancy may jeopardize both maternal and fetal well\u2010being. Although valproic acid is known for its teratogenic potential, a well-controlled patient\u2014especially one who has been seizure-free for years\u2014should not have her medication regimen altered mid\u2010pregnancy. Ideally, any switch to a safer agent (e.g., lamotrigine) should be planned and implemented prior to conception. Valproic acid works by increasing gamma-aminobutyric acid (GABA) levels and modulating sodium channels to prevent seizures. However, it is associated with teratogenic effects, including neural tube defects and cognitive disturbances, which are dose dependent. Lamotrigine, by contrast, has a lower teratogenic risk but poses challenges in the pregnant state due to altered pharmacokinetics and the risk of breakthrough seizures during titration. This 25-year-old pregnant woman has had excellent seizure control for 3 years on a low dose (500 mg daily) of valproic acid, with normal EEG and MRI findings. Given her stability, the risks associated with a mid-pregnancy conversion (such as breakthrough seizures and medication level fluctuations) outweigh the theoretical benefit of switching to lamotrigine. Key diagnostics in epilepsy management include a detailed history of seizure frequency, review of AED levels, EEG monitoring, and neuroimaging when indicated. In this case, the patient\u2019s normal EEG and MRI, combined with her long seizure-free interval, confirm that her epilepsy is well controlled. The current guidelines stress avoiding unnecessary changes to an effective AED regimen during pregnancy due to the risk of provoking breakthrough seizures, which can lead to maternal and fetal injury. In addition, any management plan must include folic acid supplementation to partially mitigate valproate\u2019s teratogenic risk and appropriate counseling regarding seizure management. Breastfeeding counseling should occur postpartum, but it is not the primary concern at this stage. Thus, the best approach is to maintain her current treatment and focus on comprehensive, quality-of-life counseling that includes discussion of the risks and benefits, rather than making a late switch to a different medication. Option A (Stop Valproic acid) is dangerous because abrupt cessation may precipitate seizure recurrence. Option B (Switch to Lamotrigine) while theoretically offering a safer teratogenic profile, is not advisable mid-pregnancy due to the risks involved in switching regimens and the challenges in dose titration during pregnancy. Option D (Counsel her about breastfeeding) is not immediately relevant to her current management during pregnancy. Option C (Quality of life counseling) is the best choice because it implies an approach of reassuring the patient, maintaining her effective regimen, and providing preemptive counseling on issues (including the importance of seizure control, folate supplementation, and close monitoring) relevant to being a pregnant woman with epilepsy. \u2022 In pregnant patients with epilepsy who are stable, avoid changing AEDs to prevent the risk of seizure recurrence.  \u2022 Valproic acid is teratogenic, but its risks are dose-dependent; if a patient is well controlled on a low dose, abrupt changes may be more harmful than beneficial if not preplanned.  \u2022 Preconception counseling is crucial for women with epilepsy to allow safe transitions to less teratogenic regimens when possible. Recent guidelines from bodies such as the International League Against Epilepsy (ILAE) and EURAP emphasize that seizure control remains the top priority in pregnant women with epilepsy. Literature supports that changes in AED therapy during pregnancy are associated with increased risks of breakthrough seizures. Moreover, careful monitoring and continuation of an effective regimen, with optimized folate supplementation, are recommended rather than a medication switch during pregnancy.",
    "exam_year": "2023",
    "exam_type": "Part I",
    "image_url": "page_6.png"
  },
  {
    "question": "Young patient presented to neurology outpatient clinic for epilepsy evaluation. He has seizure semiology inform of right upper limb tonic posturing followed by limb jerking with lack of awareness, then bilateral tonic-clonic seizure He doesn\u2019t recall the episode. He has history of 4 car accident one of them required ICU admission for 3 days.\nWhat is the best description for his seizure semiology?",
    "option_a": "Jacksonian March",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Epilepsy",
    "explanation": "This scenario describes a seizure with a focal onset in the right upper limb (suggesting involvement of the contralateral motor cortex) that evolves into impaired awareness and then progresses to a bilateral tonic-clonic phase. Such a progression is best described as a focal onset seizure with impaired awareness evolving to bilateral tonic-clonic seizure rather than a classic Jacksonian march, in which awareness is typically preserved. Focal seizures begin due to localized cortical hyperexcitability. In this patient, the initial isolated motor signs (right upper limb tonic posturing and jerking) imply a seizure focus in the left motor cortex. As the epileptiform activity propagates to involve networks related to awareness and subsequently both hemispheres, the patient experiences impaired awareness followed by secondary generalization into a bilateral tonic-clonic seizure. Patients with post-traumatic brain injury have an increased risk of developing focal epilepsies. The described seizure semiology, including the initial localized motor manifestations, subsequent loss of awareness, and final bilateral convulsive phase, is characteristic of a focal seizure with impaired awareness (previously termed complex partial seizure) evolving to a secondary generalized seizure. The differential diagnosis includes simple focal motor seizures (such as a Jacksonian march) where consciousness is maintained, versus focal onset seizures with impaired awareness. Workup should include detailed history, seizure semiology analysis, EEG monitoring (possibly video EEG), and neuroimaging (MRI) to localize the focus. The detailed history, including the traumatic brain injury from multiple car accidents, supports a secondary epileptogenesis. Management involves initiating appropriate anti-epileptic drugs (AEDs) targeted for focal seizures. In young patients, especially those who may become pregnant, medications with favorable pregnancy and lactation profiles, like lamotrigine or levetiracetam, are preferred. Preconception counseling and folate supplementation are essential components of management to reduce teratogenic risks. Option A, Jacksonian march, describes a focal motor seizure with a progressive spread of motor activity without loss of awareness. In this case, the presence of impaired awareness and progression to a bilateral seizure points away from a pure Jacksonian march. Although options B and C are not provided, the marked answer D\u2014which corresponds to a focal onset seizure with impaired awareness evolving into bilateral tonic-clonic activity\u2014is the best fit for the described semiology. A key point is that impaired awareness during a seizure distinguishes complex partial (or focal impaired awareness) seizures from simple partial seizures. Recognizing this is crucial for accurate diagnosis, localization, and subsequent management. History of head trauma should raise suspicion for post-traumatic epilepsy. Recent clinical guidelines and studies underscore the importance of accurate seizure classification for optimal AED selection. For focal seizures with impaired awareness, current evidence supports the use of AEDs that are effective in focal epilepsies and have a favorable safety profile in pregnancy, such as levetiracetam and lamotrigine. Advanced diagnostic techniques including video EEG and high-resolution MRI are recommended for precise localization of the epileptogenic focus.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 45-year-old female patient diagnosed with epilepsy currently on Lacosamide 200 mg BID and Levetiracetam 1500 mg BID. She presented to epilepsy outpatient clinic for evaluation. She reported history of generalized seizure preceded by feeling of fear and palpitation. While in the clinic she had seizure episode started with chewing spells and right hand automatism followed by bilateral generalized tonic-clonic seizure. She doesn\u2019t recall the event.\nWhich of the following is the next step in management?",
    "option_a": "Video EEG",
    "option_b": "Routine EEG",
    "option_c": "Interictal SPECT",
    "option_d": "Ictal SPECT",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question deals with the evaluation of a patient with known epilepsy who is experiencing breakthrough seizures despite being on antiepileptic drugs. The key concept is that when the clinical semiology is complex and the source of seizures is unclear, further characterization using prolonged monitoring is indicated. Video EEG is the gold standard in capturing both clinical behaviors and accompanying electrical activity, which aids in localizing the epileptogenic zone. Temporal lobe epilepsy is commonly associated with abnormal excitability in the mesial temporal structures (including the hippocampus and amygdala). Here, an aura (in this case, fear and palpitations) often represents the beginning of a focal seizure that may progress to involve neighboring networks. The sudden interruption of normal inhibitory and excitatory neurotransmission results in paroxysmal, hypersynchronous neuronal firing, which clinically evolves into automatisms (chewing and hand movements) before generalizing. The patient\u2019s description of an aura (feeling of fear and palpitations) followed by focal features (chewing spells, right hand automatism) and then generalization fits with a focal onset seizure that secondarily generalizes. This pattern is typical in temporal lobe epilepsy, where the initial focal discharge may spread to involve both hemispheres, resulting in a bilateral tonic-clonic seizure. Differential diagnoses for episodic events include non-epileptic events (e.g., psychogenic nonepileptic seizures, syncope, movement disorders) and different types of epilepsies (focal versus generalized). A routine EEG may miss ictal events due to its short duration, so prolonged video EEG monitoring, which captures both the clinical manifestations and corresponding electrical changes, is preferred. Additional advanced neuroimaging (such as ictal/interictal SPECT) is typically reserved for pre-surgical evaluation after ictal onset zone is better defined. According to current guidelines, patients with breakthrough seizures despite optimal medication dosing should undergo video EEG monitoring to refine the diagnosis and localize the epileptogenic focus, which may open up further management options (such as adjusting medication or considering surgical evaluation). When considering management in pregnancy or lactation, careful selection of antiepileptic drugs with lower teratogenic risk and close monitoring is warranted; video EEG evaluation can provide critical localization data in refractory cases to optimize future treatment plans. Option A (Video EEG) is correct because it allows prolonged recording and precise correlation between clinical events and EEG changes. Option B (Routine EEG) is less useful because its short duration may not capture the ictal event. Options C (Interictal SPECT) and D (Ictal SPECT) are less commonly used as first-line evaluations; they are more reserved for pre-surgical workups when noninvasive EEG and imaging have not localized the focus. 1. Auras such as fear and palpitations often localize to temporal lobe structures. 2. Video EEG monitoring is the most definitive method for evaluating and localizing seizures in patients with complex semiologies. 3. Focal seizures with secondary generalization require careful re-assessment for potential surgical candidacy. Recent guidelines emphasize the use of prolonged video EEG monitoring in patients with drug-resistant epilepsy or when the semiology is ambiguous. Advances in neuroimaging and electrophysiologic monitoring have improved localization, which is key to tailoring further management\u2014ranging from medication adjustments to surgical options.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 20s-year-old female known to have seizure presented to the outpatient clinic, on lacosamide 100mg BID compliant to her medication last seizure 18 months ago, examination was unremarkable. EEG showed electrical discharges, Brain MRI is normal.\nWhat is the next step?",
    "option_a": "Increase Lacosamide dose",
    "option_b": "Add Carbamazepine",
    "option_c": "Consider surgery",
    "option_d": ", though not explicitly stated, implies that no change in management is necessary (i.e., observe/continue current treatment), which is the correct approach.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Epilepsy",
    "explanation": "This question centers on the management of a patient with a history of epilepsy who has been clinically well for 18 months. The decision to change or maintain antiepileptic drug therapy is primarily based on the clinical course (i.e., seizure freedom) rather than solely on EEG findings. Epileptiform discharges on interictal EEG reflect an underlying increased neuronal excitability. However, the presence of such discharges in a clinically stable patient (seizure\u2010free for a prolonged period) does not necessarily equate to poor control. Many patients continue to have abnormal EEG findings despite adequate control with medications. Even though the patient\u2019s EEG demonstrated electrical discharges, her clinical course (18 months seizure-free) is reassuring. The MRI is normal and she is compliant on lacosamide. This scenario is common in epilepsy management and requires careful monitoring rather than escalation of therapy. The primary differentials in evaluating a patient in remission include considering whether the abnormal EEG findings indicate a need for further intervention versus being an incidental finding. Other evaluations like re-imaging are not indicated in the absence of clinical seizure activity or abnormal findings on prior imaging. Current guidelines recommend maintaining the current antiepileptic regimen if the patient has not met the conventional threshold for drug withdrawal. Generally, a seizure-free period of at least 2 years is advised before considering tapering or discontinuing medication. For women in the childbearing age group, the decision to taper should be made very cautiously due to the risks associated with seizure recurrence during pregnancy and possible teratogenicity of medications. Option A (Increase Lacosamide dose) is unnecessary as the patient is already clinically stable. Option B (Add Carbamazepine) would constitute polytherapy without clear evidence of breakthrough seizures. Option C (Consider surgery) is used for drug-resistant epilepsy, which is not the case here. Option D, though not explicitly stated, implies that no change in management is necessary (i.e., observe/continue current treatment), which is the correct approach. 1. A minimum of 2 years of seizure freedom is typically required before considering withdrawal or alteration of AED therapy. 2. Abnormal interictal EEG findings alone do not mandate changes in management if the patient is clinically seizure-free. 3. Patient compliance and clinical history are paramount in decision-making. Recent studies support that the decision to taper antiepileptic drugs should be based on the duration of seizure remission rather than EEG findings alone. Current guidelines reinforce waiting until a 2-year seizure-free period to minimize the risk of recurrence, particularly in patients with otherwise normal neuroimaging and well-controlled epilepsy.",
    "exam_year": "2023",
    "exam_type": "Part I",
    "image_url": "page_8.png"
  },
  {
    "question": "A 45-year-old female patient diagnosed with epilepsy currently on Lacosamide 200 mg BID and Levetiracetam 1500 mg BID. She presented to epilepsy outpatient clinic for evaluation. She reported history of generalized seizure preceded by feeling of fear and palpitation. While in the clinic she had seizure episode started with chewing spells and right hand automatism followed by bilateral generalized tonic-clonic seizure. She doesn\u2019t recall the event.\nWhat is the pathophysiology responsible for this case?",
    "option_a": "Trisynaptic glutamergic neuron inhibition",
    "option_b": "Trisynaptic glutamergic neuron excitation",
    "option_c": "Dentate granular cell inihibition",
    "option_d": "Dentate granular cell excitation",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question assesses your understanding of the neurophysiologic basis of temporal lobe epilepsy. The key concept is that the hippocampal formation contains a well\u2010defined excitatory neuronal circuit (the trisynaptic pathway) that plays a central role in seizure generation when dysregulated. The trisynaptic circuit in the hippocampus involves the entorhinal cortex projecting to the dentate gyrus, which then sends mossy fibers to the CA3 region, and subsequently the CA1 region via Schaffer collaterals. In temporal lobe epilepsy, hyperexcitability is often due to an imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) influences. Excessive glutamatergic excitation in this circuit leads to hyper-synchronization of neurons, precipitating seizures. Loss or dysfunction of inhibitory interneurons further exacerbates this imbalance. The patient's aura of fear and palpitations suggests involvement of limbic structures (such as the amygdala and hippocampus). The evolution of the seizure with automatisms (chewing, hand movements) progressing to generalized tonic-clonic activity is consistent with propagation from a hyperexcitable temporal lobe focus to broader cortical networks. Differentiating the underlying mechanism is important in the context of epilepsy. Other potential considerations include examining whether the pathology is due to impaired inhibition (e.g., dysfunctional dentate gating) or excessive excitation. Neuroimaging and EEG findings assist in localizing the seizure focus but do not always reveal the precise synaptic abnormalities. Management of temporal lobe epilepsy includes antiepileptic drugs targeting sodium channels and GABAergic pathways. In medically refractory cases, surgical resection of the epileptogenic focus may be considered. For women who are pregnant or lactating, drug selection must take into account teratogenic risks and drug levels, with preference for medications with a more favorable safety profile during pregnancy. Option A (Trisynaptic glutamatergic neuron inhibition) is incorrect because inhibition would reduce excitability rather than promote seizures. Option B (Trisynaptic glutamatergic neuron excitation) is correct as it highlights the excessive excitatory transmission in the hippocampal circuit. Option C (Dentate granular cell inhibition) misrepresents the role of the dentate gyrus, which normally serves as an inhibitory gate\u2014its dysfunction (i.e., failure to properly filter excitatory input) contributes to seizure activity, but the option does not directly address the excitatory cascade. Option D (Dentate granular cell excitation) is less specific and does not capture the well-established role of the trisynaptic pathway in temporal lobe epilepsy. 1. The trisynaptic circuit\u2019s hyperexcitability is a hallmark of temporal lobe epilepsy. 2. Loss of the normal inhibitory 'dentate gate' contributes to excessive excitation and seizure propagation. 3. Auras like fear are classical manifestations of temporal lobe seizure onset. Recent research emphasizes the role of network reorganization and synaptic plasticity within the hippocampus in temporal lobe epilepsy. Studies utilizing advanced neuroimaging and electrophysiologic mapping have reinforced the concept that excessive glutamatergic transmission within the trisynaptic circuit is fundamental to seizure generation and propagation in TLE.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young male presented to the ER with first time generalized tone-clonic seizure, with no previous seizure episodes, and no epilepsy risk factors. Physical examination, MRI, and EEG were normal. What is the percentage of seizure recurrence in 2 years for this patient?",
    "option_a": "10 %",
    "option_b": "30 %",
    "option_c": "50 %.",
    "option_d": "77 %.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "The question explores the recurrence risk after a first unprovoked seizure in a patient with normal evaluation. The concept is that recurrence risk is a critical factor in deciding whether to initiate antiepileptic therapy after a first seizure. A first unprovoked generalized seizure may occur due to transient alterations in neuronal excitability. In the absence of structural abnormalities, abnormal EEG findings, or genetic predisposition, the underlying brain function is generally preserved, resulting in a relatively lower recurrence risk compared to patients with additional risk factors. In patients with a first seizure and normal neurologic evaluation (normal MRI and EEG), the likelihood of a subsequent seizure is modest. This influences management decisions as aggressive treatment may not be warranted after a single event. Differential considerations include provoked seizures (due to metabolic, toxic, or febrile illnesses) versus an unprovoked seizure. Normal neuroimaging and EEG findings help confirm the absence of an overt epileptogenic lesion, thereby guiding the risk stratification for recurrence. Current guidelines suggest that after a first unprovoked seizure, the decision to commence lifelong antiepileptic medication should weigh the recurrence risk. Studies indicate that in patients with normal evaluation, the 2-year recurrence rate is approximately 30%. In women contemplating pregnancy, the risk-benefit ratio of AED initiation is even more critical given the potential teratogenic effects of these medications. In all cases, individualized decision making is emphasized. Option A (10%) underestimates the risk. Option B (30%) is in line with the evidence for patients with a normal workup. Option C (50%) and Option D (77%) significantly overstate the risk and are more in line with patients who have multiple risk factors (such as abnormal imaging or EEG findings). 1. Approximately 30% of patients with a first unprovoked seizure and normal workup will experience a recurrence within 2 years. 2. Normal EEG and MRI findings lower the risk but do not eliminate the chance of recurrence. 3. Management decisions after a first seizure are individualized, often balancing the risk of recurrence against the side effects of long-term AED therapy. Recent meta-analyses and longitudinal studies continue to support that the recurrence risk after a first unprovoked seizure in patients with a normal evaluation approximates 30%. Guidelines from epilepsy societies now emphasize shared decision-making, as the benefit of early AED initiation must be weighed against potential medication side effects and, in women of childbearing age, the implications for future pregnancy.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "An 12-year-old patient presented with history of seizure that started 3 years ago. The parents describe seizure semiology inform of frequent staring episode that cause poor school performance. Attached picture of EEG.\nWhich of the following is the most likely gene mutation responsible for patient seizure type?",
    "option_a": "KNCT-1",
    "option_b": "KNCN-1",
    "option_c": "GABRA-1",
    "option_d": "\u2026??",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "This case describes a 12\u2010year\u2010old with frequent, brief episodes of impaired awareness (staring spells) and poor school performance. Such episodes are classically seen in absence seizures, a subtype of idiopathic generalized epilepsy. The diagnosis is supported by the characteristic EEG findings (typically 3 Hz spike\u2010and\u2010wave discharges). Absence seizures are thought to result from abnormal oscillations within the thalamocortical circuits. Genetic predisposition contributes via mutations affecting neuronal ion channels and receptors. Mutations in genes encoding GABA receptor subunits (such as GABRA1, which codes for the \u03b11 subunit of the GABA_A receptor) can disrupt inhibitory neurotransmission, promoting the synchronous neuronal firing that underlies the spike\u2010wave discharges observed on EEG. Although other genes (e.g., CACNA1H or GABRG2) are also implicated, within the provided options GABRA1 is a recognized culprit in generalized epilepsies. Clinically, children with absence seizures often present with frequent, brief, and subtle impairment of awareness \u2013 episodes that may be mistaken for daydreaming. The resulting interruption of academic and daily activities explains the poor school performance. The EEG picture clinches the diagnosis. The evaluation of suspected absence epilepsy includes a detailed history and an EEG. Differential diagnoses include: (1) inattentiveness related to ADHD, (2) focal impaired awareness seizures, and (3) non-epileptic staring. The typical 3 Hz spike\u2013wave pattern on EEG helps differentiate absence seizures from other conditions. The first-line treatment for absence seizures is often ethosuximide or valproic acid. Management tailored to the genetic background is not usually required in routine practice, but understanding the role of mutations (like in GABRA1) can be important for genetic counseling and research. In counseling families, note that absence epilepsy typically responds well to these medications. In pregnancy or lactation, ethosuximide or valproate (with appropriate risk discussion and monitoring) can be used if indicated, although the teratogenic risk of valproate makes ethosuximide a preferable choice in female patients of childbearing potential. Option A (KNCT-1) and Option B (KNCN-1) use nomenclature not typically associated with the classical genetic mutations in absence epilepsy. Option C (GABRA1) is an acceptable answer based on its established association with generalized epilepsies. Option D is not specified. Therefore, within these choices, Option C is correct. 1. Always consider absence seizures in school-age children with frequent staring episodes and resultant academic difficulties. 2. The classic EEG finding is a 3 Hz spike\u2013wave discharge. 3. Many idiopathic generalized epilepsies can have a genetic basis, with GABA receptor subunit mutations playing a pivotal role. Recent research continues to refine the genetic landscape of idiopathic generalized epilepsies. Although multiple genes (including CACNA1H and GABRG2) are implicated, mutations in GABRA1 have been repeatedly reported in cases of generalized epilepsy. This emphasizes the heterogeneity of these disorders and the evolving understanding of their molecular underpinnings.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 35-year-old male, presented to the emergency room with cluster of seizures few hours ago. He is on Lacosamide 100 mg BID and reported good compliance to the medication. No epilepsy risk factors. No witnessed seizure event while in the ER. He has history of congenital heart disease. Which of the following is the next step in the management?",
    "option_a": "Add Topiramate",
    "option_b": "IV Phenytoin",
    "option_c": "IV Levetiracetam",
    "option_d": "Increase Lacosamide dose",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "The patient is a 35\u2010year\u2010old male with a history of epilepsy who presents with a cluster of seizures despite adherence to his maintenance medication (lacosamide). In the acute setting, rapid seizure termination is the goal, and selection of the medication must consider safety profiles, particularly given his congenital heart disease. Breakthrough seizure clusters in patients on chronic antiseizure medications may occur due to suboptimal dosing or fluctuations in drug levels. Lacosamide, while effective, has a known side effect of PR interval prolongation, which poses a risk in predisposed cardiac conditions. Co-administration of an antiseizure drug that does not exacerbate cardiac conduction issues is essential. The patient\u2019s presentation with a cluster, in the absence of witnessed seizure activity in the ER, suggests that he may be experiencing interictal clusters rather than a prolonged status epilepticus. His congenital heart disease makes drugs with potential cardiotoxicity less desirable. Evaluation includes confirming medication compliance, considering potential metabolic or drug interactions, and assessing cardiac status. Differential considerations include non-epileptic events, medication side effects, and metabolic causes. In an emergent setting, IV loading is the mainstay. For acute management, IV levetiracetam is widely endorsed as a first-line agent because of its rapid onset, ease of administration, and lack of significant cardiac conduction effects. IV phenytoin, although a common antiepileptic, poses risks in patients with underlying cardiac abnormalities. An increase in lacosamide could worsen conduction issues, and adding topiramate is not suitable for immediate control in the ER setting. Pregnancy and lactation: IV levetiracetam is considered relatively safe, but always weigh risk\u2013benefit in pregnant patients with epilepsy. Option A (Add Topiramate) is not preferred in an acute scenario. Option B (IV Phenytoin) is avoided due to its cardiotoxic potential. Option C (IV Levetiracetam) is optimal given its safe cardiac profile and effectiveness in acute seizure management. Option D (Increase Lacosamide dose) risks further cardiac conduction issues given the patient\u2019s history of congenital heart disease. 1. When managing acute seizures in patients with cardiac comorbidities, choose medications with minimal cardiac effects. 2. IV levetiracetam has emerged as a popular choice due to its rapid administration and favorable side-effect profile. 3. Always reassess a patient\u2019s current medication regimen before adding or adjusting medications in an emergency. Current guidelines and recent studies support the use of IV levetiracetam for acute breakthrough seizures, particularly in patients at risk for cardiac complications. Its efficacy and safety profile make it a first-line option in many emergency protocols.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young patient with developmental delay and multiple seizure types. He is on Clobazam 10 mg BID, Levetiracetam 1500 mg BID, and Valproic acid. EEG report: slow spikes and waves 1-1.5 Hz. Which of the following is the best management for this patient?",
    "option_a": "Hemispherectomy",
    "option_b": "Vagal nerve stimulation",
    "option_c": "Corpus callosotomy",
    "option_d": "Add fourth ASM",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "This scenario involves a young patient with developmental delay, multiple seizure types, and a characteristic EEG showing slow spike\u2013wave discharges (1\u20131.5 Hz), all consistent with Lennox-Gastaut Syndrome (LGS), a severe pediatric epileptic encephalopathy. LGS is notoriously refractory to treatment with medications alone. LGS involves diffuse cerebral dysfunction with abnormal thalamocortical circuits contributing to a variety of seizure types \u2013 including tonic, atonic (drop attacks), and absence seizures. The slow spike\u2013wave pattern on EEG reflects widespread network dysregulation. The syndrome often results from genetic, structural, or metabolic origins. Patients with LGS frequently present with multiple seizure types that are resistant to medical management. The presence of developmental delay further complicates management. The slow spike-wave pattern is a diagnostic hallmark and indicates a poor response to traditional antiseizure medications. Diagnosis is based on clinical presentation, developmental history, and EEG findings. Differential diagnoses include other epileptic encephalopathies, such as Dravet syndrome or West syndrome, but the typical slow spike\u2013wave pattern (1\u20131.5 Hz) in a slightly older child is characteristic of LGS. The management of LGS is challenging. While multiple antiseizure medications are often used, palliative surgical options play an important role. Corpus callosotomy is a well-established procedure for reducing the frequency and severity of drop attacks (atonic seizures) in LGS. Vagal nerve stimulation (VNS) is another option but generally is considered when corpus callosotomy is not feasible or as adjunctive therapy. Hemispherectomy is reserved for cases with unilateral, intractable epileptogenic foci and is not appropriate here. In pregnancy or lactation, surgical decisions require multidisciplinary discussion, and medical treatment must consider teratogenic risks. Option A (Hemispherectomy) is not indicated since the epilepsy is not lateralized to one hemisphere. Option B (Vagal nerve stimulation) is a palliative treatment option but is typically less effective than corpus callosotomy for drop attacks. Option C (Corpus callosotomy) is the established palliative surgical approach for reducing drop attacks in LGS and is therefore the best answer. Option D (Add fourth ASM) is generally not favored, as polypharmacy has diminishing returns in LGS. 1. LGS is a refractory epilepsy syndrome that often requires consideration of surgical palliative procedures. 2. Corpus callosotomy can significantly reduce the morbidity related to drop attacks. 3. EEG findings in LGS (slow spike\u2013wave discharges) help clinch the diagnosis. Recent guidelines and studies continue to support corpus callosotomy as a key intervention in LGS for patients with predominantly atonic (drop) seizures, particularly when medical management is insufficient. Newer therapeutic modalities and adjunctive therapies are under investigation but have yet to replace the established role of corpus callosotomy in appropriate candidates.",
    "exam_year": "2023",
    "exam_type": "Part I"
  }
]